DOCSLIB.ORG

1 Tuesday, 15 November 2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Tuesday, 15 November 2011 1 Tuesday, 15 November 2011 2 (9.30 am) 3 DR BRIAN McCLELLAND (continued) 4 Questions by MR MACKENZIE 5 THE CHAIRMAN: Good morning. Yes, Mr Mackenzie? 6 MR MACKENZIE: Good morning, sir. We move on to a new topic 7 today, topic C2, which is the non-introduction in 8 Scotland of surrogate testing for non-A non-B Hepatitis, 9 and our witness today is Dr Brian McClelland. 10 THE CHAIRMAN: Yes. 11 MR MACKENZIE: Good morning, Dr McClelland. 12 A. Good morning. 13 Q. We don't have to look at your CV again but we know that, 14 I think, between 1979 and 2001 you were director of the 15 Edinburgh and Southeast Scotland Blood Transfusion 16 Service. Is that correct? 17 A. That's correct. 18 Q. And I think you retired from the SNBTS in 2009. 19 A. That's correct. 20 Q. Could we, please, look at your statement you provided on 21 this topic. It's [PEN0170754] and what I would like to 22 do, doctor, is go through your statement and from time 23 to time ask you various questions and also look at some 24 of the documents you have referred to, plus one or two 25 others as well. 1 1 You say in your statement -- your first heading is 2 "Opinions of the importance of non-A non-B post 3 transfusion hepatitis in the UK between 1980-1989". 4 You say that before considering the particular 5 question we asked you, you thought it may be useful to 6 the Inquiry to provide a personal view on the apparent 7 persistence of the belief over the years 1980 to 1989 8 that non-A non-B post transfusion hepatitis was not an 9 important problem in the UK. And one of the themes 10 underlying this history is the view that was taken of 11 NANBH in the UK from around 1980 to the discovery of 12 Hepatitis C in 1989: 13 "Many of the decisions taken or not taken can only 14 be understood in the context of a widely held view that 15 despite an increasing body of evidence to the contrary, 16 this condition was rarely transmitted by blood and was 17 usually not particularly serious." 18 You say: 19 "I have tried to assemble some evidence that 20 illustrates how this view may have originated." 21 We will go on to look at the various papers. 22 Am I right in thinking, doctor, that the papers you 23 list are largely looking at the prevalence of 24 post-transfusion hepatitis in the UK rather than 25 focusing on the seriousness of the disease? 2 1 A. Yes, absolutely. 2 Q. Looking at these papers in turn, please, the first one 3 you refer to is the Medical Research Council Blood 4 Transfusion Research Committee in 1974. This is the 5 year of publication of a report of a study carried out 6 for the UK MRC of hepatitis in recipients of blood 7 components. 8 You explain that: 9 "This study is described in some detail since it is 10 one of only four substantial prospective studies of PTH 11 in the UK." 12 Can you explain, please, doctor, what does 13 "prospective study" mean and how does that differ 14 perhaps with a predictive study? 15 A. Well, in broad terms, actually the term is quite 16 widely -- it is used in a variety of senses, but in 17 broad terms it implies a study where you, as it were, 18 define the questions that you are asking and then carry 19 out work in advance, according to a planned schedule, to 20 test the answers to those questions. 21 The -- the sort of gold standard -- and we will come 22 back to this I'm sure -- of a prospective study is 23 what's called a prospective randomised clinical trial, 24 which is designed in such a way -- it is designed, if it 25 is well designed, to -- to compare at least two groups 3 1 of patients, one group who receives a particular form of 2 treatment or intervention, which could be a diagnostic 3 test or anything in principle, and the other group who 4 either is a control group that receives -- does not 5 receive that intervention or treatment or that receives 6 another one, in which case it could be comparing two 7 treatments. Those studies, if properly designed, should 8 see that the groups of patients who are enrolled to the 9 treatment group and the control group, if you like, are 10 randomly selected, and one of the tests that you apply 11 in analysing a study like that is to see that actually 12 the make-up of gender, age, social class, co-morbidities 13 and so on, is very similar between the two groups. 14 There are, you know, a number of very well evolved 15 criteria for -- to determine the quantity of design and 16 execution of the prospective randomised control trial. 17 At a sort of lower -- below the gold standard, if 18 you like, there are studies which set out to look at 19 what happens in the future when you initiate an action 20 in the present, and those are broadly called 21 "prospective studies", but they don't all by any means 22 tick the -- all the boxes required for a very high 23 quality study. 24 Q. Yes, and predictive study, what is that? 25 A. It is not a term I have ever used. I don't really know 4 1 what it means. 2 Q. I see. We might give it some context if we see it in 3 some of the literature we look at over the course of 4 today. That may help. 5 A. I'm happy to try and do that. I would make the 6 distinction more between a prospective study, which is 7 the sort of characteristics that I have sketched out, 8 and an observational study, which would be essentially 9 looking at what has happened, something that you are 10 already doing and you collect the information about what 11 has been done for a number of years in the past and you 12 then try to draw some inferences about the relationships 13 between one event, for example, the use of a treatment 14 or a test, and another event, which is the development 15 or non-development of an illness in the patient. 16 But those studies are always very difficult to 17 interpret because of the risk of confounding factors, 18 such as associations between a particular type of 19 patient and the probability of getting a particular 20 treatment, and it's extremely difficult, even with the 21 use of quite complicated statistical techniques -- in 22 fact I would say it's impossible -- to draw conclusions 23 about the cause and effect from these retrospective type 24 of studies. 25 Q. Yes. 5 1 A. But they are very useful for generating hypotheses, for 2 saying it looks as though something is happening because 3 of something else, then you go on to do a properly 4 designed prospective study to test that hypothesis. 5 Q. Yes. I understand. 6 Returning, please, to your statement and the MRC 7 study, you explain that: 8 "From mid 1969 to the end of December 1971, patients 9 at the Central Middlesex Hospital ..." 10 Participated in giving a pre-transfusion blood 11 sample for ALT and viral studies. 12 We see that of the 2,184 patients who were 13 transfused during the study period, follow-up was 14 completed on 768 who received an average of 3.7 units of 15 blood per patient. 16 Over the page of your statement, we see: 17 "Routine testing of donor blood for Hepatitis B only 18 began during the last five months of the study period: 19 "Raised ALT values were found after transfusion in 20 158 patients." 21 Six of whom underwent liver biopsy: 22 "None showed histological features typical of acute 23 viral hepatitis." 24 Then you quote: 25 "The authors stated that these 158 patients were 6 1 investigated for conditions other than viral hepatitis, 2 eg drug induced liver injury. It was arbitrarily 3 decided that where such other potential causes existed, 4 the patient would not be regarded as suffering from 5 viral hepatitis. On this basis, eight patients 6 (1 per cent) were judged to have had post-transfusion 7 hepatitis. Sustained elevation of ALT without other 8 clinical features of hepatitis was present in 35 9 patients." 10 You then again quote: 11 "The authors concluded that 'the overall incidence 12 of icteric and anicteric hepatitis in the present survey 13 (1 per cent) is low compared with the incidence found in 14 prospective studies in Japan (65 per cent) ... USA 15 (18 per cent) ... and Germany (14 per cent).' However 16 if PTH had been defined to include all the patients with 17 ..." 18 That's the end of quote and you go on to say: 19 "However, if PTH had been defined to include all the 20 patients with persistently elevated ALT, the PTH rate 21 would have been 35/768 or 4.5 per cent. If PTH had been 22 defined to include patients with any elevation of ALT 23 following transfusion, 158 of the 768 patients 24 (21 per cent) would have been defined as having PTH." 25 That paragraph perhaps just illustrates the 7 1 difficulties at the time, doctor, in trying to 2 accurately conclude the true rate of post-transfusion 3 hepatitis based on elevated ALT levels.
Load more

Recommended publications
  • The Impact of Hepatitis B Surface Antigen on Natural Killer Cells In
    Medizinische Fakultät der Universität Duisburg-Essen Aus der Klinik für Gastroenterologie und Hepatologie The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection Inauguraldissertation zur Erlangung des Doktorgrades der Medizin durch die Medizinische Fakultät der Universität Duisburg-Essen Vorgelegt von Yanqin Du aus Hubei, China 2020 1 Diese Dissertation wird via DuEPublico, dem Dokumenten- und Publikationsserver der Universität Duisburg-Essen, zur Verfügung gestellt und liegt auch als Print-Version vor. DOI: 10.17185/duepublico/74388 URN: urn:nbn:de:hbz:464-20210623-112949-4 Alle Rechte vorbehalten. Dekan: Herr Univ.-Prof. Dr. med. J. Buer 1. Gutachter/in: Herr Univ.-Prof. Dr. med. H. H. Wedemeyer 2. Gutachter/in: Frau Priv.-Doz. Dr. rer. nat. W. Bayer 3. Gutachter/in: Herr Prof. Dr. rer. nat. C. Watzl Tag der mündlichen Prüfung: 20. April. 2021 2 List of publication Du, Y., Anastasiou, E.O., Strunz, B., Scheuten, J., Bremer, B., Kraft A., Kleinsimglinhaus K., Todt, D., Broering, R., Hardtke-Wolenski, M., Wu, J., Yang, D., Dittmer, U., Lu, M., Cornberg, M., Björkström, K.N., Khera, T., and Wedemeyer, H. The impact of hepatitis B surface antigen on natural killer cells patients with chronic hepatitis B patients. Liver Int. 2021 Apr 1. doi: 10.1111/liv.14885. 3 Table of Contents 1. Introduction ............................................................................................................. 7 1.1. Global Prevalence and public health burden ..................................................... 7 1.2. HBV virology ..................................................................................................... 8 1.2.1. HBV structure .............................................................................................. 8 1.2.2. Viral life cycle .............................................................................................. 9 1.3. Natural history and clinical manifestation of HBV infection .......................... 10 1.3.1.
    [Show full text]
  • Hepatitis B: Prevalence, Hope
    Hepatitis B: Prevalence, Hope The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Hedley-Whyte, John, and Debra R Milamed. "Hepatitis B: Prevalence, Hope." The Ulster Medical Journal 88, no. 2 (2019): 118-123. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41971766 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Ulster Med J 2019;88(2):118-123 Medical History Hepatitis B: Prevalence, Hope John Hedley-Whyte, M.D., F.A.C.P., F.R.C.A., Debra R. Milamed, M.S. Accepted: 15th January 2019 Provenance: Internally reviewed Key Words: Mentors, Virology, were responsible for wide-ranging advances in alleviation of pandemic Hepatitis B. This quartet of physician scientists INTRODUCTION each had outstanding World War II records and post-war In the transcript of his Nobel Oration for the 1976 Award in guidance: each was a personable and talented leader2,3,4,5,6,7. Physiology or Medicine, Baruch S. Blumberg refers to David EDUCATION Surrey Dane nine times.1 Dane joined the Queen’s Belfast Microbiology Department in 1955. He was soon promoted David Maurice Surrey Dane was educated at Charterhouse to Senior Lecturer, then Reader. In 1966 Dane was called to School, Surrey, England (Fig.2). In October 1942 he was a Chair of Microbiology at the University of London tenable gazetted as a Second Lieutenant in the British Army8.
    [Show full text]
  • Hepatitis B: Prevalence, Hope John Hedley-Whyte, M.D., F.A.C.P., F.R.C.A., Debra R
    Ulster Med J 2019;88(2):118-123 Medical History Hepatitis B: Prevalence, Hope John Hedley-Whyte, M.D., F.A.C.P., F.R.C.A., Debra R. Milamed, M.S. Accepted: 15th January 2019 Provenance: Internally reviewed Key Words: Mentors, Virology, were responsible for wide-ranging advances in alleviation of pandemic Hepatitis B. This quartet of physician scientists INTRODUCTION each had outstanding World War II records and post-war In the transcript of his Nobel Oration for the 1976 Award in guidance: each was a personable and talented leader2,3,4,5,6,7. Physiology or Medicine, Baruch S. Blumberg refers to David EDUCATION Surrey Dane nine times.1 Dane joined the Queen’s Belfast Microbiology Department in 1955. He was soon promoted David Maurice Surrey Dane was educated at Charterhouse to Senior Lecturer, then Reader. In 1966 Dane was called to School, Surrey, England (Fig.2). In October 1942 he was a Chair of Microbiology at the University of London tenable gazetted as a Second Lieutenant in the British Army8. In at the Bland-Sutton Institute and the Middlesex Hospital. 1943, Dane joined the British Parachute Regiment and was Baruch S. (Barry) Blumberg (Fig. 1), David Surrey Dane seconded to the Special Air Service (SAS). Having been (Fig. 2), Michael G.P. Stoker (Fig. 3) and Wolf Szmuness Fig 2. David Surrey Dane (1923-1998). Photograph reproduced with permission of Vox Sanguinis18 exclusively for this Medical History. After a distinguished academic career at Queen’s Belfast and London University, Professor David Surrey Dane contributed greatly to donor screening protocols to assure the safety of the British blood supply.
    [Show full text]
  • Prevention of Viral Hepatitis in the Nordic Countries and Germany
    PUBLISHED BY THE VIRAL HEPATITIS PREVENTION BOARD (VHPB) June 2004 EDITORIAL Volume 12 - Number 3 This issue of Viral Hepatitis examines viral hepatitis prevention and control activities in CONTENTS Germany and the Nordic countries, based on conclusions that were reached during the Viral Hepatitis Prevention Board meeting, held October 13-14, 2003 in Berlin, Germany. EDITORIAL ...................................... 1 Limitations of selective risk-group immunisation Prevention of viral hepatitis in the One of the key topics for discussion during the Berlin meeting was that of hepatitis B Nordic countries immunisation targeted to risk groups. This policy has been adopted by all of the Nordic Epidemiology of hepatitis A in Sweden - the countries, based on relatively low hepatitis B virus (HBV) prevalence rates in those regions, but same old story? . .2 does not comply with the 1992 WHO recommendation that all countries include hepatitis B Hepatitis A and B outbreaks among injecting vaccination in their national universal vaccination programmes by 1997 – recommendations that drug users in the Nordic countries . .3 have been implemented by many other European Union Member States, such as Germany. Hepatitis B surveillance, epidemiology, and Besides a risk-group approach, Germany has started implementing universal hepatitis B prevention strategies in the Nordic countries . .5 vaccination programmes for infants, children, and adolescents since 1995. Problems associated with the presence of In view of continuing hepatitis B virus outbreaks, some of which can be traced to nosocomial HBsAg-positive children in day-care centres . .6 transmission and clusters of cases among young children in day-care centres, high-risk Investigation of a cluster of nosocomial immunisation strategies will need to be re-examined.
    [Show full text]
  • Expert Report to the Infected Blood Inquiry: Hepatitis
    Expert Report to the Infected Blood Inquiry: Hepatitis January 2020 with addendum © Crown copyright 2020 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at www.infectedbloodinquiry.org.uk Any enquiries regarding this publication should be sent to us [email protected] 01/20 Printed on paper containing 75% recycled fibre content minimum Printed in the UK by the APS Group Expert Report to the Infected Blood Inquiry: Hepatitis Explanatory Note Please note that the paragraph numbers below relate to numbered questions in the Letter of Instruction which was sent to the Hepatitis Expert Group by the Infected Blood Inquiry 15.1 An explanation of what hepatitis is. Please note this section also addresses the Supplemental Question 6.4 Hepatitis refers to inflammation of the liver, regardless of the cause. A diagnosis of hepatitis is usually made by detection of biochemical abnormalities in the blood, in particular measuring enzymes released from liver cells (hepatocytes) damaged by inflammation. Two enzymes are key to liver function testing; alanine aminotransaminase (ALT) and aspartate aminotransferase (AST). Hepatitis is usually diagnosed when one (or more) of these enzymes is raised above normal ranges in the context of other results. Definitions of normal range vary with those for ALT and AST most commonly quoted as 5-40 IU/l.
    [Show full text]
  • 088(1)047.Pdf (377.0Kb)
    International Contributions toward the Conquest of Polio The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Hedley-Whyte, John, and Debra Milamed. 2018. International Contributions toward the Conquest of Polio. Ulster Medical Journal 88 (1): 47-54. Published Version https://www.ums.ac.uk/umj088/088(1)047.pdf Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:38030313 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Ulster Med J 2019;88(1):47-54 Medical History International Contributions toward the Conquest of Polio John Hedley-Whyte, M.D., F.A.C.P., F.R.C.A., Debra R. Milamed, M.S. Accepted: 5th of October 2018 Provenance: internally peer-reviewed. Key Words: Polio, Vaccines THE GOLDEN YEARS INTRODUCTION The recruitment of noted virologist George Williamson Auchinvole Dick by Eric Ashby2,3,4, Paul Mellon’s friend and In October 1986 Paul Mellon flew his own jet to Aldergrove, beneficiary, led to vital improvements in the production and thence to Ulster-American Folk Park near Omagh. To safety of polio vaccine (Fig. 2). Dick was to be awarded by Mellon’s surprise, he was met by a delegation headed by Park Johns Hopkins University the title “Hero of Public Health”5. Director Denis MacNeice. Paul Mellon was then escorted to Eric Ashby became Lord Ashby of Brandon4.
    [Show full text]
  • Vaccinations in Response to Epidemics” Which Were Staged in Province Oriental in January and February 1958
    new piece of apparently supportive evidence has come in, I have first of all acted as devil’s advocate. I have contacted scientists from appropriate fields, to sample their views. And unless I have been certain that something is sound, I have always erred on the side of caution. My American and British publishers, too, have played an important role here, with the very careful scientific and legal readings which the book was given before publication. Not surprisingly, they wanted to be certain that I was able to justify everything I’d written. Perhaps the best evidence that I have not bent the facts to the theory, or rushed to premature judgement, would be the thrice-given testimony given by Gaston Ninane in 1992, that the Koprowski vaccines had been made in “chimpanzee kidney cells”. After I told Dr Ninane that the scientific literature at the time had mentioned only “monkey kidney cells” he suddenly retracted, saying that this was what he had intended to say – and I accepted that he had made a mistake. It would have been far easier, had I been intent on forcing the issue, simply to quote the words that he had said, and to ignore the subsequent denial. In the end, it took nine years of further research before I was finally convinced that what he had originally told me was the truth. But what of “untruths” told by the other side? There are quite a few examples of these to be found in The River, and others that can be discerned in the rivulets that run through the endnotes, or between the lines.
    [Show full text]
  • International Contributions Toward the Conquest of Polio John Hedley-Whyte, M.D., F.A.C.P., F.R.C.A., Debra R
    Ulster Med J 2019;88(1):47-54 Medical History International Contributions toward the Conquest of Polio John Hedley-Whyte, M.D., F.A.C.P., F.R.C.A., Debra R. Milamed, M.S. Accepted: 5th of October 2018 Provenance: internally peer-reviewed. Key Words: Polio, Vaccines THE GOLDEN YEARS INTRODUCTION The recruitment of noted virologist George Williamson Auchinvole Dick by Eric Ashby2,3,4, Paul Mellon’s friend and In October 1986 Paul Mellon flew his own jet to Aldergrove, beneficiary, led to vital improvements in the production and thence to Ulster-American Folk Park near Omagh. To safety of polio vaccine (Fig. 2). Dick was to be awarded by Mellon’s surprise, he was met by a delegation headed by Park Johns Hopkins University the title “Hero of Public Health”5. Director Denis MacNeice. Paul Mellon was then escorted to Eric Ashby became Lord Ashby of Brandon4. Camp Hill Cottage, where his grandfather, Thomas Mellon had been born in 1813. His grandfather left in 1817 for Baltimore, Maryland (memoir published privately 1885). The visages of Grandfather Thomas and Paul, both in their 70s are remarkably similar1 (Fig. 1). Fig 2. Lord Ashby of Brandon (1904-92), oil on canvas by Ruskin Spear, CBE, RA (1911-1990) 1960. From the Queen’s University Belfast Art Collection, and reproduced with their permission. Eric Ashby, Kt, Ph.D., F.R.S., Vice Chancellor, President and Fig 1. Paul Mellon, oil on canvas, by William Franklin Draper Chancellor of the Queen’s University, Belfast, entered the City of (1912-2003), 1974, 48.25 x 40.12 inches, image no.
    [Show full text]
  • Almeida J D, Rubenstein D & Stotl E J. New Antigen-Antibody System In
    CC/NUMBER 9 FEBRUARY 28, 1983 This Week's Citation Classic Almeida J D, Rubenstein D & Stotl E J. New antigen-antibody system in Australia- antigen-positive hepatitis. Lancet 2:1225-7, 1971. [Dept. Virology, Royal Postgrad. Med. Sch., London, and Clinical Res. Ctr., Northwick Park Hosp., Harrow, Middlesex, England] The paper reported that the double shelled "We started with a preparation rich Dane particle of what is now hepatitis B an- in Dane particles and subjected it to tigen, but which was then Australia antigen, several degradative procedures. The could be degraded by detergents to reveal end products of these experiments an internal component that was antigenical- were always checked in the electron ly distinct from the surface of the particle. microscope by the negative staining [The SCI® indicates that this paper has been technique as well as being inoculated cited in over 345 publications since 1971.] onto a wide range of tissue cultures. Luckily, since one of my major inter- ests is the visualisation of the interac- tion between virus and antibodies, we were able to recognise that Dane par- ticles split with detergent released an June D. Almeida inner component that became covered Wellcome Research Laboratories with antibody that must have been Beckenham, Kent BR3 3BS present in the original serum. Almost England immediately we dropped the tissue culture aspect of the work that had yielded no positive results and turned December 22, 1982 our attention to this new phenomenon. It didn't take long to establish that sera "It has been said that Columbus, sail- positive for hepatitis B antigen always ing in the wrong direction and using a had antibody to this internal compo- false premise, nevertheless discovered nent or core, and that this system was America.
    [Show full text]
  • Studies on the Pathogenesis and the Early Events of Hepadnavirus
    'za. \,'13 EVENTS OF HEPADNAVIRUS REPLICATION Ming QIAO M.B., B.S. Department of Microbiology and lmmunology University of Adelaide Adelaide South Australia A thesis submitted to the University of Adelaide in fulfilment of the requirements for the degree of Doctor of Philosophy June 1993 /rvuanàuÅ tq() + CONTENTS ABSTRACT v¡i DECLARATION x ACKNOWLEDGEM ENTS x¡ ABBREVIAT¡ONS x¡¡¡ PUBLICATIONS xvi GHAPTER 1: INTRODUCTION 1.1 HBV Epidemiology and Transmission 1 1.2 The HePadnaviridae 3 1.3 Structure of HBV Particles 5 1.4 Antigenic and Biophysical Characteristics of Hepatitis B Surface Antigen Particles 7 1.5 Hepadnavirus Genome Organisation I 1.5.1 Genome Siructure I 1.5.2ORF-S and lts Function s 1.5.3 Virus Nucleocaps¡d (ORF'C) 11 1.5.4 The DNA Polymerase Gene and lts Product 1 3 1.5.5 The ORF-X and Product 15 1.6 Transcrlption and Gontrol Elements of the HePadnavirus Genome 17 1.6.1 The 3.5kb RNA Transcript and lts Promoter 17 1.6.2The 2.1 and2.4 RNA Transcripts and Their Promoters 1e 1.6.3 The 0.7kb RNA Transcript and lts Promoter 1e 1.6.4 Transcriptional Enhancer Elements 20 1.7 Hepadnavirus Genome Replication 2'l SteP One: Formation of CCC DNA 22 il Step Two: Synthesis and Packaging of pregenomic RNA 22 Step Three: Synthesis of Minus Strand 23 Step Four: Synthesis of Plus Strand 24 1.8 Host Range and Tissue Tropism 26 1.9 The Hepadnavirus Receptor and Virus Entry 27 1.10 Serological Diagnosis of Hepatitis B 29 1.11 Pathogenesis of HBV lnfection 32 1 .1 1 .1 Hepatocyte Injury and lmmunological Mechanisms 32 1.11.2 Mechanisms of HBV
    [Show full text]
  • Transfusion Microbiology Edited by John A
    Cambridge University Press 978-0-521-45393-6 - Transfusion Microbiology Edited by John A. J. Barbara, Fiona A. M. Regan and Dame Marcela Contreras Frontmatter More information Transfusion Microbiology © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-45393-6 - Transfusion Microbiology Edited by John A. J. Barbara, Fiona A. M. Regan and Dame Marcela Contreras Frontmatter More information Transfusion Microbiology Edited by Professor John A. J. Barbara, MA (Cantab), MSc, PhD, FIBiol, FRCPath Formerly Head of National Transfusion Microbiology Laboratories, National Blood Service, UK Emeritus Consultant in Microbiology to NHS Blood and Transplant Visiting Professor in Transfusion Microbiology, University of the West of England, Bristol, UK Dr Fiona A. M. Regan NHSBT and Hammersmith Hospitals NHS Trust, London, UK Professor Dame Marcela Contreras, MD, FRCPath, FRCP, FMedSci, DBE Royal Free and University College Hospitals Medical School, London, UK Formerly Director of Diagnostics, Development and Research, National Blood Service, UK © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-45393-6 - Transfusion Microbiology Edited by John A. J. Barbara, Fiona A. M. Regan and Dame Marcela Contreras Frontmatter More information CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sa˜o Paulo, Delhi Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK Published in the United States of America by Cambridge University Press, New York www.cambridge.org Information on this title: www. cambridge.org/9780521453936 # Cambridge University Press 2008 This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.
    [Show full text]
  • Imperial Display, Apes, Angels, and the Return of Monsieur Émile Zola
    Edward Hooper, “Dephlogistication, Imperial Display, Apes, Angels, and the Return of Monsieur Émile Zola”, Atti dei Convegni Lincei; 2003; 187; 27-230. This is part of the proceedings of the round table conference on "Origin of HIV and Emerging Persistent Viruses", published as ISBN 88-218-0885-8 © 2003 The Accademia Nazionale dei Lincei and Edward Hooper. Dephlogistication,* Imperial Display, Apes, Angels, and the Return of Monsieur Émile Zola. New developments in the origins of AIDS controversy, including some observations about ways in which the scientific establishment may seek to limit open debate and flow of information on “difficult” issues. Edward Hooper Abstract. Since the mid-1950s, in laboratories around the world, oral polio vaccines (OPVs) have been routinely amplified in locally-prepared primate kidney cell cultures, before being diluted and fed by mouth to local populations. During the fifties, it was possible for a virologist to prepare polio vaccines in the primate cells of his or her choice: to do this contravened neither scientific rules nor recommendations of the day. Some OPV developers (such as Albert Sabin and collaborators) reported the fact that local preparation of the vaccine had occurred in the country of use, such as the U.S.S.R.; while others (such as Hilary Koprowski and collaborators) reported * According to the Oxford English Dictionary, this rather impressive word means a “depriving of phlogiston”, or a “relieving of inflammation”. It is used in both contexts in the course of this paper, but overall I prefer to think of it in a slightly wider context – that of a “reduction in hot air levels”.
    [Show full text]